PKD2

Across TCGA pan-cancer cohorts, PKD2 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated PKD2 data layer compared with 26 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher PKD2 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated PKD2 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and PDAC show a favorable association.

CCRCC, UCEC, and LSCC are the cancer types where PKD2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Median	III,IV	0.863	0.569	.012	8	view →
UCEC	OS	Median	II,III,IV	0.620	1.000	.011	8	view →
LSCC	OS	Tertile	III,IV	0.384	0.901	.014	5	view →
PDAC	DFS	Quartile	III,IV	0.979	0.571	.017	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

PKD2–CCRCC (OS)

Open the CCRCC breakdown →